clinicaloncologyКлинический случай в онкологииClinical Case in Oncology3034-14773034-4018ОНКОПРАКТИК10.62546/3034-1477-2024-2-4-35-43clinicaloncology-90Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCASE REPORTSРадиоиндуцированная ангиосаркома молочной железы. Клинический случай и обзор литературыRadiation-induced breast angiosarcoma. Clinical case and literature reviewhttps://orcid.org/0009-0007-6393-7561ГеркИ. А.GerkI. A.

Герк Иван АлександровичРоссия, 198255, Санкт-Петербург, пр. Ветеранов, д. 56

Ivan Aleksandrovich Gerk56 Veteranov Ave., St. Petersburg, 198255, Russiа

dr.ivangerk@gmail.comСПб ГБУЗ «Городской клинический онкологический диспансер»РоссияSt. Petersburg City Clinical Oncology DispensaryRussian Federation202428042025243543Copyright © Герк И.А., 20252025Герк И.А.Gerk I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncocase.ru/jour/article/view/90

Радиоиндуцированная ангиосаркома (РИАС) молочной железы  — редкое, но агрессивное осложнение лучевой терапии, которое развивается у пациенток после лечения рака молочной железы. Данное заболевание характеризуется неблагоприятным прогнозом, обусловленным поздней диагностикой, быстрым прогрессированием и ограниченной эффективностью существующих терапевтических подходов. Цель данной работы — систематизация современных данных по диагностике и лечению РИАС на основе обзора литературы и анализа клинического случая пациентки, у которой заболевание развилось через несколько лет после лечения рака молочной железы. Несмотря на  проведенное радикальное иссечение, заболевание сопровождалось быстрыми рецидивами и  резистентностью к терапии, что подчеркивает сложность ведения таких пациентов. Представленный случай демонстрирует необходимость индивидуального подхода и дальнейших исследований для оптимизации лечебных стратегий.

Radiotherapy-induced angiosarcoma (RIAS) of the breast is a rare but aggressive complication of radiation therapy that develops in patients following breast cancer treatment. This malignancy is characterized by a poor prognosis due to delayed diagnosis, rapid tumor progression, and the limited effectiveness of current treatment modalities. The aim of this study is to review modern approaches in the diagnosis and management of RIAS and to present a clinical case of a patient who developed RIAS several years following breast cancer treatment. Despite radical surgical resection, this case demonstrated rapid recurrence and resistance to therapy, highlighting the challenges in management. The presented case emphasizes the need for an individualized approach and further research to optimize treatment strategies.

ангиосаркома молочной железырадиоиндуцированная ангиосаркомавторичное злокачественное новообразованиеbreast angiosarcomaradiation-induced angiosarcomasecondary cancerReferencesWHO Classification of Tumours Editorial Board. Soft tissue and bone tumours // WHO Classification of Tumours. 5th ed. Lyon, France: IARC Press, 2020.WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours // WHO Classification of Tumours. 5th ed. Lyon, France: IARC Press, 2020.Guo T., Zhang L., Chang N.E. et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions // Genes Chromosomes Cancer. 2011. Vol. 50, No. 1. Р. 25–33. https://doi.org/10.1002/gcc.20827.Guo T., Zhang L., Chang N.E. et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions // Genes Chromosomes Cancer. 2011. Vol. 50, No. 1. Р. 25–33. https://doi.org/10.1002/gcc.20827.Verdin V., Mattart L., Cusumano P.G. et al. Angiosarcoma associated with radiation therapy after treatment of breast cancer: Retrospective study on ten years // Cancer Radiother. 2021. Vol. 25, No. 2. Р. 114–118. https://doi.org/10.1016/j.canrad.2020.05.020.Verdin V., Mattart L., Cusumano P.G. et al. Angiosarcoma associated with radiation therapy after treatment of breast cancer: Retrospective study on ten years // Cancer Radiother. 2021. Vol. 25, No. 2. Р. 114–118. https://doi.org/10.1016/j.canrad.2020.05.020.Friedrich A.K.U., Reisenbichler E.S., Heller D.R. et al. Characteristics and long-term risk of breast angiosarcoma // Ann. Surg. Oncol. 2021. Vol. 28. Р. 5112–5118. https://doi.org/10.1245/s10434-021-09689-2.Friedrich A.K.U., Reisenbichler E.S., Heller D.R. et al. Characteristics and long-term risk of breast angiosarcoma // Ann. Surg. Oncol. 2021. Vol. 28. Р. 5112–5118. https://doi.org/10.1245/s10434-021-09689-2.Jackson K.M., Grumley J.G. Radiation-induced breast angiosarcoma: Updates on a rare disease // Curr. Breast Cancer Rep. 2024. Vol. 16, No. 2. Р. 177–184. https://doi.org/10.1007/s12609-024-00542-5.Jackson K.M., Grumley J.G. Radiation-induced breast angiosarcoma: Updates on a rare disease // Curr. Breast Cancer Rep. 2024. Vol. 16, No. 2. Р. 177–184. https://doi.org/10.1007/s12609-024-00542-5.Rombouts A.J., Huising J., Hugen et al. Assessment of radiotherapy-associated angiosarcoma after breast cancer treatment in a Dutch population-based study // JAMA Oncol. 2019. Vol. 5, No. 2. Р. 267–269. https://doi.org/10.1001/jamaoncol.2018.6643.Rombouts A.J., Huising J., Hugen et al. Assessment of radiotherapy-associated angiosarcoma after breast cancer treatment in a Dutch population-based study // JAMA Oncol. 2019. Vol. 5, No. 2. Р. 267–269. https://doi.org/10.1001/jamaoncol.2018.6643.Conti M., Morciano F., Rossati et al. Angiosarcoma of the breast: overview of current data and multimodal imaging findings // J. Imaging. 2023. Vol. 9, No. 5. Р. 94. https://doi.org/10.3390/jimaging9050094.Conti M., Morciano F., Rossati et al. Angiosarcoma of the breast: overview of current data and multimodal imaging findings // J. Imaging. 2023. Vol. 9, No. 5. Р. 94. https://doi.org/10.3390/jimaging9050094.Salminen S.H., Sampo M.M., Böhling T.O. et al. Radiation-associated angiosarcoma of the breast: analysis of diagnostic tools in a registry-based population // Acta Radiol. 2022. Vol. 63, No. 1. Р. 22–27. https://doi.org/10.1177/0284185120980142.Salminen S.H., Sampo M.M., Böhling T.O. et al. Radiation-associated angiosarcoma of the breast: analysis of diagnostic tools in a registry-based population // Acta Radiol. 2022. Vol. 63, No. 1. Р. 22–27. https://doi.org/10.1177/0284185120980142.Guram S., Covelli A.M., O’Neill A.C. et al. Multidisciplinary intervention in radiation-associated angiosarcoma of the breast: patterns of recurrence and response to treatment // Ann. Surg. Oncol. 2022. Vol. 29, No. 1. Р. 522–532. https://doi.org/10.1245/s10434-021-10477-1.Guram S., Covelli A.M., O’Neill A.C. et al. Multidisciplinary intervention in radiation-associated angiosarcoma of the breast: patterns of recurrence and response to treatment // Ann. Surg. Oncol. 2022. Vol. 29, No. 1. Р. 522–532. https://doi.org/10.1245/s10434-021-10477-1.Gutkin P.M., Ganjoo K.N., Lohman M. et al. Angiosarcoma of the breast: management and outcomes // Am. J. Clin. Oncol. 2020. Vol. 43, No. 11. Р. 820–825. https://doi.org/10.1097/COC.0000000000000753.Gutkin P.M., Ganjoo K.N., Lohman M. et al. Angiosarcoma of the breast: management and outcomes // Am. J. Clin. Oncol. 2020. Vol. 43, No. 11. Р. 820–825. https://doi.org/10.1097/COC.0000000000000753.Salminen S.H., Wiklund T., Sampo M.M. et al. Treatment and prognosis of radiation-associated breast angiosarcoma in a nationwide population // Ann. Surg. Oncol. 2020. Vol. 27. Р. 1002–1010. https://doi.org/10.1245/s10434-019-08085-1.Salminen S.H., Wiklund T., Sampo M.M. et al. Treatment and prognosis of radiation-associated breast angiosarcoma in a nationwide population // Ann. Surg. Oncol. 2020. Vol. 27. Р. 1002–1010. https://doi.org/10.1245/s10434-019-08085-1.Li G.Z., Fairweather M., Wang J. et al. Cutaneous radiation-associated breast angiosarcoma: radicality of surgery impacts survival // Ann. Surg. 2017. Vol. 265, No. 4. Р. 814–820. https://doi.org/10.1097/SLA.0000000000001753.Li G.Z., Fairweather M., Wang J. et al. Cutaneous radiation-associated breast angiosarcoma: radicality of surgery impacts survival // Ann. Surg. 2017. Vol. 265, No. 4. Р. 814–820. https://doi.org/10.1097/SLA.0000000000001753.Gullett N.P., Delman K., Folpe A.L. et al. National surgical patterns of care: regional lymphadenectomy of breast sarcomas // Am. J. Clin. Oncol. 2007. Vol. 30, No. 5. Р. 461–465. https://doi.org/10.1097/COC.0b013e31804b40f4.Gullett N.P., Delman K., Folpe A.L. et al. National surgical patterns of care: regional lymphadenectomy of breast sarcomas // Am. J. Clin. Oncol. 2007. Vol. 30, No. 5. Р. 461–465. https://doi.org/10.1097/COC.0b013e31804b40f4.Palta M., Morris C.G., Grobmyer S.R. et al. Angiosarcoma after breast-conserving therapy: long-term outcomes with hyperfractionated radiotherapy // Cancer. 2010. Vol. 116, No. 8. Р. 1872–1878. https://doi.org/10.1002/cncr.24995.Palta M., Morris C.G., Grobmyer S.R. et al. Angiosarcoma after breast-conserving therapy: long-term outcomes with hyperfractionated radiotherapy // Cancer. 2010. Vol. 116, No. 8. Р. 1872–1878. https://doi.org/10.1002/cncr.24995.Kronenfeld J.P., Crystal J.S., Ryon E.L. et al. Clinical outcomes for primary and radiation-associated angiosarcoma of the breast with multimodal treatment: long-term survival is achievable // Cancers (Basel). 2021. Vol. 13, No. 15. Р. 3814. https://doi.org/10.3390/cancers13153814.Kronenfeld J.P., Crystal J.S., Ryon E.L. et al. Clinical outcomes for primary and radiation-associated angiosarcoma of the breast with multimodal treatment: long-term survival is achievable // Cancers (Basel). 2021. Vol. 13, No. 15. Р. 3814. https://doi.org/10.3390/cancers13153814.Cohen-Hallaleh R.B., Smith H.G., Smith R.C. et al. Radiation-induced angiosarcoma of the breast: outcomes from a retrospective case series // Clin. Sarcoma Res. 2017. Vol. 7. Р. 1–6. https://doi.org/10.1186/s13569-017-0081-7.Cohen-Hallaleh R.B., Smith H.G., Smith R.C. et al. Radiation-induced angiosarcoma of the breast: outcomes from a retrospective case series // Clin. Sarcoma Res. 2017. Vol. 7. Р. 1–6. https://doi.org/10.1186/s13569-017-0081-7.Penel N., Bui B.N., Bay J.O. et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study // J. Clin. Oncol. 2008. Vol. 26, No. 32. Р. 5269–5274. https://doi.org/10.1200/JCO.2008.17.3146.Penel N., Bui B.N., Bay J.O. et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study // J. Clin. Oncol. 2008. Vol. 26, No. 32. Р. 5269–5274. https://doi.org/10.1200/JCO.2008.17.3146.Ju T., Foster D., Titan A. et al. Skin angiography-assisted mastectomy in secondary breast angiosarcoma: complete clinical response after neoadjuvant immunotherapy // Breast J. 2021. Vol. 27, No. 9. Р. 723–725. https://doi.org/10.1111/tbj.14270.Ju T., Foster D., Titan A. et al. Skin angiography-assisted mastectomy in secondary breast angiosarcoma: complete clinical response after neoadjuvant immunotherapy // Breast J. 2021. Vol. 27, No. 9. Р. 723–725. https://doi.org/10.1111/tbj.14270.Anderson E. Sarcoma of the breast: implication for extent of therapy // Surgery. 1994. Vol. 116. Р. 505–509.Anderson E. Sarcoma of the breast: implication for extent of therapy // Surgery. 1994. Vol. 116. Р. 505–509.Torres K.E., Ravi V., Kin K. et al. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer // Ann. Surg. Oncol. 2013. Vol. 20. Р. 1267–1274. https://doi.org/10.1245/s10434-012-2755-y.Torres K.E., Ravi V., Kin K. et al. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer // Ann. Surg. Oncol. 2013. Vol. 20. Р. 1267–1274. https://doi.org/10.1245/s10434-012-2755-y.Lagrange J.L., Ramaioli A., Chateau M.C. et al. Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases // Radiology. 2000. Vol. 216, No. 1. Р. 197–205. https://doi.org/10.1148/radiology.216.1.r00jl02197.Lagrange J.L., Ramaioli A., Chateau M.C. et al. Sarcoma after radiation therapy: retrospective multiinstitutional study of 80 histologically confirmed cases // Radiology. 2000. Vol. 216, No. 1. Р. 197–205. https://doi.org/10.1148/radiology.216.1.r00jl02197.Constantinidou A., Sauve N., Stacchiotti S. et al. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study // ESMO Open. 2020. Vol. 5, No. 4. e000787. https://doi.org/10.1136/esmoopen2020-000787.Constantinidou A., Sauve N., Stacchiotti S. et al. Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study // ESMO Open. 2020. Vol. 5, No. 4. e000787. https://doi.org/10.1136/esmoopen2020-000787.Lahat G., Dhuka A.R., Lahat S. et al. Outcome of locally recurrent and metastatic angiosarcoma // Ann. Surg. Oncol. 2009. Vol. 16, No. 9. Р. 2502–2509. https://doi.org/10.1245/s10434-009-0569-3.Lahat G., Dhuka A.R., Lahat S. et al. Outcome of locally recurrent and metastatic angiosarcoma // Ann. Surg. Oncol. 2009. Vol. 16, No. 9. Р. 2502–2509. https://doi.org/10.1245/s10434-009-0569-3.Young R.J., Natukunda A., Litière S. et al. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials // Eur. J. Cancer. 2014. Vol. 50, No. 18. Р. 3178–3186. https://doi.org/10.1016/j.ejca.2014.10.004.Young R.J., Natukunda A., Litière S. et al. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials // Eur. J. Cancer. 2014. Vol. 50, No. 18. Р. 3178–3186. https://doi.org/10.1016/j.ejca.2014.10.004.Van der Graaf W.T., Blay J.Y., Chawla S.P. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial // Lancet. 2012. Vol. 379, No. 9829. Р. 1879–1886. https://doi.org/10.1016/S0140-6736(12)60651-5.Van der Graaf W.T., Blay J.Y., Chawla S.P. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial // Lancet. 2012. Vol. 379, No. 9829. Р. 1879–1886. https://doi.org/10.1016/S0140-6736(12)60651-5.Agulnik M., Schulte B., Robinson S. et al. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma // Eur. J. Cancer. 2021. Vol. 154. Р. 201–208. https://doi.org/10.1016/j.ejca.2021.06.027.Agulnik M., Schulte B., Robinson S. et al. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma // Eur. J. Cancer. 2021. Vol. 154. Р. 201–208. https://doi.org/10.1016/j.ejca.2021.06.027.Maki R.G., D’Adamo D.R., Keohan M.L. et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas // J. Clin. Oncol. 2009. Vol. 27, No. 9. Р. 3133–3140. https://doi.org/10.1200/JCO.2008.20.4495.Maki R.G., D’Adamo D.R., Keohan M.L. et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas // J. Clin. Oncol. 2009. Vol. 27, No. 9. Р. 3133–3140. https://doi.org/10.1200/JCO.2008.20.4495.Agulnik M., Yarber J.L., Okuno S.H. et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas // Ann. Oncol. 2013. Vol. 24, No. 1. Р. 257–263. https://doi.org/10.1093/annonc/mds237.Agulnik M., Yarber J.L., Okuno S.H. et al. An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas // Ann. Oncol. 2013. Vol. 24, No. 1. Р. 257–263. https://doi.org/10.1093/annonc/mds237.Florou V., Rosenberg A.E., Wieder E. et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution // J. Immunother Cancer. 2019. Vol. 7, No. 1. Р. 213. https://doi.org/10.1186/s40425-019-0689-7.Florou V., Rosenberg A.E., Wieder E. et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution // J. Immunother Cancer. 2019. Vol. 7, No. 1. Р. 213. https://doi.org/10.1186/s40425-019-0689-7.Wagner M.J., Othus M., Patel S.P. et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) // J. Immunother Cancer. 2021. Vol. 9, No. 8. Р. e002990. https://doi.org/10.1136/jitc-2021-002990.Wagner M.J., Othus M., Patel S.P. et al. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) // J. Immunother Cancer. 2021. Vol. 9, No. 8. Р. e002990. https://doi.org/10.1136/jitc-2021-002990.Grilley-Olson J.E., Allred J.B., Schuetze S. et al. A multicenter phase II study of cabozantinib + nivolumab for patients with advanced angiosarcoma previously treated with a taxane (Alliance A091902) // J. Clin. Oncol. 2023. Vol. 41, Suppl. 16. Р. 11503. https://doi.org/10.1200/JCO.2023.41.16_suppl.11503.Grilley-Olson J.E., Allred J.B., Schuetze S. et al. A multicenter phase II study of cabozantinib + nivolumab for patients with advanced angiosarcoma previously treated with a taxane (Alliance A091902) // J. Clin. Oncol. 2023. Vol. 41, Suppl. 16. Р. 11503. https://doi.org/10.1200/JCO.2023.41.16_suppl.11503.

The authors declare that there are no conflicts of interest present.